Literature DB >> 19237297

Strategies for minimizing complications of neutropenia: prophylactic myeloid growth factors or antibiotics.

John R Wingard1, Mohamed Elmongy.   

Abstract

Chemotherapy-induced myelosuppression is a major complication of chemotherapy regimens used to treat solid tumors and lymphomas. Myelosuppression is frequently accompanied by neutropenic fever and other complications and threatens the ability to maintain chemotherapy dose intensity. Two prophylaxis strategies have been evaluated to mitigate the infectious complications of myelosuppression: myeloid growth factors and antibiotic. Clinical trials and meta-analyses of trial data indicate substantial benefit to these agents in selected patients. Each type of prophylaxis has advantages and disadvantages. Additional studies are needed to optimize how these are employed in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19237297     DOI: 10.1016/j.critrevonc.2009.01.003

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  12 in total

Review 1.  Febrile neutropenia in hematologic malignancies.

Authors:  Michael K Keng; Mikkael A Sekeres
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

2.  Understanding the risk for infection in patients with neutropenia.

Authors:  Jean A Klastersky; Anne-Pascale Meert
Journal:  Intensive Care Med       Date:  2015-07-14       Impact factor: 17.440

3.  Current spectrum of bacterial infections in patients with nosocomial fever and neutropenia.

Authors:  Davood Yadegarynia; Alireza Fatemi; Masih Mahdizadeh; Reihaneh Kabiri Movahhed; Mohammad Afshin Alizadeh
Journal:  Caspian J Intern Med       Date:  2013

4.  Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study).

Authors:  Pere Gascón; Matti Aapro; Heinz Ludwig; Carsten Bokemeyer; Mario Boccadoro; Matthew Turner; Kris Denhaerynck; Karen MacDonald; Ivo Abraham
Journal:  Support Care Cancer       Date:  2015-08-27       Impact factor: 3.603

Review 5.  Granulocyte colony-stimulating factors as prophylaxis against febrile neutropenia.

Authors:  Sol Cortés de Miguel; Miguel Ángel Calleja-Hernández; Salomón Menjón-Beltrán; Inmaculada Vallejo-Rodríguez
Journal:  Support Care Cancer       Date:  2014-10-07       Impact factor: 3.603

6.  Impact of Pretreatment Neutrophil Count on Chemotherapy Administration and Toxicity in Dogs with Lymphoma Treated with CHOP Chemotherapy.

Authors:  Q Fournier; J-C Serra; I Handel; J Lawrence
Journal:  J Vet Intern Med       Date:  2017-12-04       Impact factor: 3.333

7.  Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study).

Authors:  M Aapro; H Ludwig; C Bokemeyer; P Gascón; M Boccadoro; K Denhaerynck; A Krendyukov; M Gorray; K MacDonald; I Abraham
Journal:  Ann Oncol       Date:  2016-11       Impact factor: 32.976

Review 8.  Supportive care in hemato-oncology: a review in light of the latest guidelines.

Authors:  Eren Gündüz; Zafer Gülbaş
Journal:  Turk J Haematol       Date:  2012-03-05       Impact factor: 1.831

Review 9.  Myeloid toxicity of cancer treatment.

Authors:  Sandra Kurtin
Journal:  J Adv Pract Oncol       Date:  2012-07

Review 10.  Harnessing the immune system in the battle against breast cancer.

Authors:  Elizabeth S Nakasone; Sara A Hurvitz; Kelly E McCann
Journal:  Drugs Context       Date:  2018-02-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.